SEC Form 4 · accession 0001140361-26-030107
Roivant Sciences Ltd. · ROIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Venker
Officer — President & Immunovant CEO
Period of report
Jul 27, 2026
Accepted (ET)
Jul 29, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001635088
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jul 27, 2026 | M | 200,000 | $3.85 | A | 1,813,063 | D | |
| Common SharesF1 | Jul 27, 2026 | S | 200,000 | $34.95 | D | 1,613,063 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.85 | Jul 27, 2026 | M | 200,000 | D | — | Apr 19, 2032 | Common Stock | 200,000 | 4,044,834 | D |
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.62 to $35.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F2Reflects an award of stock options to purchase Common Shares that is fully vested.
Remarks
Exhibit 24 - Power of Attorney